Skip to main content

Advertisement

SpringerLink
Log in

Expression change of ezrin as a prognostic factor in primary osteosarcoma

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Osteosarcoma is a life-threatening malignancy that most often occurs in teenagers. Ezrin is a cytoskeleton linker protein that is actively involved in the metastatic capacity of cancer cells. In this study, we investigated the expression change of ezrin after preoperative chemotherapy and its prognostic value in patients with primary osteosarcoma. Ezrin mRNA expression level of initial biopsy specimens and resected tumor specimens after preoperative chemotherapy of 25 patients who had primary osteosarcoma with ezrin expression was detected by semiquantitative reverse transcription polymerase chain reaction (RT–PCR) to evaluate the expression change of ezrin. In addition, the prognostic factors and the relationship between the expression change of ezrin and the clinical characteristics were analyzed. Expression change of ezrin was found in 64% of all 25 patients. The expression change of ezrin had good relation with histology (P = 0.037), grade (P = 0.006), chemotherapy response (P = 0.017), and metastasis or recurrence (P = 0.041). The 2-year overall survival and event-free survival were associated with expression change of ezrin (P = 0.001 and P = 0.002, respectively) and response to preoperative chemotherapy (P = 0.001 and P = 0.012, respectively). Our findings suggest that expression change of ezrin is an independent positive prognostic factor in non-metastatic osteosarcoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Damron TA, Ward WG, Stewart A. Osteosarcoma, chondrosarcoma, and Ewing’s sarcoma. National cancer data base report. Clin Orthop Relat Res. 2007;459:40–7.

    Article  PubMed  Google Scholar 

  2. Meyers PA, et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the memorial sloan-kettering experience. J Clin Oncol. 1992;10:5–15.

    PubMed  CAS  Google Scholar 

  3. Bacci G, et al. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer. 2006;106:1154–61.

    Article  PubMed  Google Scholar 

  4. Kalifa C, et al. Chemotherapy in osteogenic sarcoma: the experience of the pediatric department of the Gustave Roussy institute. Cancer Treat Res. 1993;62:347–9.

    Article  PubMed  CAS  Google Scholar 

  5. Bieling P, et al. Tumor size and prognosis in aggressively treated osteosarcoma. J Clin Oncol. 1996;14:848–58.

    PubMed  CAS  Google Scholar 

  6. Taylor WF, et al. Prognostic variables in osteosarcoma: a multi-institutional study. J Natl Cancer Inst. 1989;81:21–30.

    Article  PubMed  CAS  Google Scholar 

  7. Clark JC, Dass CR, Choong PF. A review of clinical and molecular prognostic factors in osteosarcoma. J Cancer Res Clin Oncol. 2008;134:281–97.

    Article  PubMed  CAS  Google Scholar 

  8. Buddingh EP, et al. Prognostic factors in pulmonary metastasized high-grade osteosarcoma. Pediatr Blood Cancer. 2010;54:216–21.

    PubMed  Google Scholar 

  9. Mangeat P, Roy C, Martin M. ERM proteins in cell adhesion and membrane dynamics. Trends Cell Biol. 1999;9:187–92.

    Article  PubMed  CAS  Google Scholar 

  10. Vaheri A, et al. The ezrin protein family: membrane-cytoskeleton interactions and disease associations. Curr Opin Cell Biol. 1997;9:659–66.

    Article  PubMed  CAS  Google Scholar 

  11. Bretscher A, Edwards K, Fehon RG. ERM proteins and merlin: integrators at the cell cortex. Nat Rev Mol Cell Biol. 2002;3:586–99.

    Article  PubMed  CAS  Google Scholar 

  12. Gautreau A, et al. Ezrin, a plasma membrane-microfilament linker, signals cell survival through the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci USA. 1999;96:7300–5.

    Article  PubMed  CAS  Google Scholar 

  13. Wang JW, et al. Identification of metastasis-associated proteins involved in gallbladder carcinoma metastasis by proteomic analysis and functional exploration of chloride intracellular channel 1. Cancer Lett. 2009;281:71–81.

    Article  PubMed  CAS  Google Scholar 

  14. Hunter KW. Ezrin, a key component in tumor metastasis. Trends Mol Med. 2004;10:201–4.

    Article  PubMed  CAS  Google Scholar 

  15. Ilmonen S, Vaheri A, Asko-Seljavaara S, Carpen O. Ezrin in primary cutaneous melanoma. Mod Pathol. 2005;18:503–10.

    Article  PubMed  CAS  Google Scholar 

  16. Weng WH, Ahlen J, Astrom K, Lui WO, Larsson C. Prognostic impact of immunohistochemical expression of ezrin in highly malignant soft tissue sarcomas. Clin Cancer Res. 2005;11:6198–204.

    Article  PubMed  CAS  Google Scholar 

  17. Khanna C, et al. The membrane cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med. 2004;10:182–6.

    Article  PubMed  CAS  Google Scholar 

  18. Picci P, et al. Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy. Regional mapping of viable and nonviable tumor. Cancer. 1985;56:1515–21.

    Article  PubMed  CAS  Google Scholar 

  19. Bacci G, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli’s 4th protocol. Eur J Cancer. 2001;37:2030–9.

    Article  PubMed  CAS  Google Scholar 

  20. Bielack SS, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1702 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol. 2002;20:627–9.

    Article  Google Scholar 

  21. Sohn JH, et al. Efficacy of pre- and postoperative chemotherapy in patients with osteosarcoma of the extremities. Cancer Res Treat. 2001;33:520–6.

    Google Scholar 

  22. Zhang Y, et al. The membrane-cytoskeleton organizer ezrin is necessary for hepatocellular carcinoma cell growth and invasiveness. J Cancer Res Clin Oncol. 2006;132:685–97.

    Article  PubMed  CAS  Google Scholar 

  23. Kim MS, Song WS, Cho WH, Lee SY, Jeon DG. Ezrin expression predicts survival in stage IIB osteosarcomas. Clin Orthop Relat Res. 2007;459:229–36.

    Article  PubMed  Google Scholar 

  24. Xu-dong S, et al. Expression of ezrin correlates with lung metastasis in Chinese patients with osteosarcoma. Clin Invest Med. 2009;32:180–8.

    Google Scholar 

  25. Bentzen SM, et al. Prognostic factors in osteosarcomas. A regression analysis. Cancer. 1988;62:194–202.

    Article  PubMed  CAS  Google Scholar 

  26. Hauben EI, Weeden S, Pringle J, Van Marck EA, Hogendoorn PC. Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup. Eur J Cancer. 2002;38:1218–25.

    Article  PubMed  CAS  Google Scholar 

  27. Park HR, et al. Ezrin in osteosarcoma: comparison between conventional high-grade and central low-grade osteosarcoma. Pathol Res Pract. 2006;202:509–15.

    Article  PubMed  CAS  Google Scholar 

  28. Provisor AJ, et al. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children’s Cancer Group. J Clin Oncol. 1997;15:76–84.

    PubMed  CAS  Google Scholar 

  29. Rosen G, et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer. 1982;49:1221–30.

    Article  PubMed  CAS  Google Scholar 

  30. Salas S, et al. Ezrin and alpha-smooth muscle actin are immunohistochemical prognostic markers in conventional osteosarcomas. Virchows Arch. 2007;451:999–1007.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We are thankful to Dr. Jun Qiang Yin and Dr. ChangYe Zou for support and constant encouragement.

Author information

Authors and Affiliations

  1. Department of Orthopaedic Surgery, Musculoskeletal Tumor Center, the First Affiliated Hospital of Sun Yat-Sen University, No.58 ZhongShan 2nd Road, 510080, GuangZhou, GuangDong, China

    Yao Fei Wang, Jing Nan Shen, Xian Biao Xie, Jin Wang & Gang Huang

Authors
  1. Yao Fei Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jing Nan Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xian Biao Xie
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jin Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Gang Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jing Nan Shen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wang, Y.F., Shen, J.N., Xie, X.B. et al. Expression change of ezrin as a prognostic factor in primary osteosarcoma. Med Oncol 28 (Suppl 1), 636–643 (2011). https://doi.org/10.1007/s12032-010-9684-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-010-9684-z

Keywords

Search

Navigation